RCM
DMII

Radcliffe Capital Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Radcliffe Capital Management’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.74M Buy
575,721
+114
+0% +$1.14K 0.43% 60
2025
Q4 		$5.7M Buy
+575,607
New +$5.69M 0.31% 62

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Radcliffe Capital Management's DMII Position: Q1 2026 in Review

Radcliffe Capital Management increased its Drugs Made In America Acquisition II Corp (DMII) stake by 0.02% in Q1 2026, buying an estimated $1.14K and bringing the position to 575,721 shares worth $5.74M. The position accounts for 0.43% of the portfolio, ranked #60.

Radcliffe Capital Management first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Radcliffe Capital Management held 575,721 shares of Drugs Made In America Acquisition II Corp worth $5.74M as of Q1 2026.
  • Radcliffe Capital Management bought 114 Drugs Made In America Acquisition II Corp shares in Q1 2026, an estimated $1.14K.
  • Drugs Made In America Acquisition II Corp made up 0.43% of Radcliffe Capital Management's portfolio in Q1 2026, its #60 holding.
  • Radcliffe Capital Management first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Radcliffe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.